Get started

Monkeypoxstocks

NBY effective against Monkeypox ! 20X Upside Analyst Rating!!!NovaBay Pharmaceuticals, Inc. (NBY) owns Avenova, which is EPA listed as an effective disinfectant for monkeypox. On 5/20/2022 Ascendiant Capital Markets brokerage set a price target of $4.00 for NovaBay Pharmaceuticals, Inc. (NBY). The stock is now only 0.20usd. Before the pandemic news, on their last earnings, they mentioned that Avenova Spray unit sales increased 15% with record-high units sold through the OTC channel. NovaBay CEO: "we expect the majority of 2022 topline growth to come in the second half of this year." The stock had only insider buys recently, the average being $0.45. Only 10.976Mil MARKET CAP The falling wedge in the chart is a bullish sign. I think we can expect at least a reversal to the $0.64 resistance. Looking forward to read your opinion about it.
AMEX:NBYLong
by TopgOptions
TNXP Tonix Pharmaceuticals produces the Monkeypox Vaccine ! Tonix is a producer of the TNX-801 vaccine, effective against Smallpox and Monkeypox. But that`s not all! They have a strong balance sheet, Cash and Cash Equivalents Totaled Approximately $140 Million VS its mk cap of only $44.03Mil. Seth Lederman, M.D., Chief Executive Officer of Tonix: “Tonix is making meaningful strides developing our rich portfolio of high impact product candidates,” “By the end of this year, we expect to have five central nervous system (CNS) programs in the clinic, led by our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development. Enrollment has begun for TNX-102 SL in a registration-enabling-Phase 3 clinical trial. TNX-102 SL trials in Long COVID and PTSD are also expected to initiate enrollment in the second quarter of 2022.” TNX-2900 received Orphan-Drug designation by the FDA for the treatment of PWS in March 2022. On this strong pipeline, on 4/18/2022 Noble Financial Initiated Coverage on TNXP with an Outperform rating and a price target of $19.20, while Alliance Global Partners has a price target of $64. I expect TNXP Tonix Pharmaceuticals to be at least $10 per share. Looking forward to read your opinion about it.
NASDAQ:TNXPLong
by TopgOptions
2